Navigation Links
Debiopharm Group™ and Aurigene Nominate Development Candidate
Date:9/13/2010

LAUSANNE, Switzerland, and BANGALORE, India, Sept. 13 /PRNewswire/ -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd. (Aurigene), a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway. Debio 0617 has started IND enabling studies and is expected to enter clinical development in 2012.

Debiopharm and Aurigene have been collaborating for five years. In November 2008, Aurigene's fragment-based drug delivery technology platform had generated potent leads against the target. Both companies signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialise Debio 0617. They defined a target molecular profile at the beginning of the program. Now, 20 months later, both teams have successfully identified the development candidate which better fits the initial target molecular profile.

"What exciting news! As we expected, this program has delivered a development candidate molecule as well as several potential follow-on compounds," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group™. "Once again, Aurigene has demonstrated its dedication and professionalism."

"This represents an important success not just for this scientific program, but also for the strategic path that was established through this agreement between Debiopharm and Aurigene. This is a truly synergistic relationship that takes advantage of the proven experience, expertise and processes at Debiopharm, coupled with the speed, flexibility and high-quality science at Aurigene. It also paves the way for a larger synergistic alliance between the companies," added CSN Murthy, CEO of Aurigene.

About Debiopharm Group™ Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: www.debiopharm.com.

About AurigeneEstablished in Bangalore, India, in 2002, Aurigene Discovery Technologies Ltd. is a drug discovery biotech focused on small molecule and peptide drug discovery. With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated Drug Discovery company focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates in oncology, metabolic disorders, autoimmune diseases and anti-infectives.. Aurigene has- a proven track record of successful partnerships with big and medium-sized pharma and biotech companies globally. Aurigene has 10 drug discovery collaborations and a pipeline of 20 discovery programs at various stages, from Hit Generation to late-stage Pre-Clinical Optimization, and has filed over 25 patents across its programs.

For more information on Aurigene, please visit www.aurigene.com. Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & communication
Tel.: +41 (0)21 321 01 11
Fax: +41 (0)21 321 01 69
mwagner@debiopharm.com Additional Media Contacts

In London
Maitland
Brian Hudspith
Tel: +44 (0)20 7379 5151
bhudspith@maitland.co.ukAurigene Contacts
Rajshree KT
Head Strategic Alliances
Tel: +91 (0)40 4465 71 32
Fax: +91 (0)40 4465 71 32
rajshree_kt@aurigene.com

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1 212-845-4292
Fax: +1 212-845-4260
martina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
2. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
3. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
4. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
5. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
6. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
7. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
8. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
9. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
10. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):